Featured News
784Wire StoriesCyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator for...
- 601Wire Stories
Renesas Launches World’s Most Highly Integrated Advanced Bluetooth Low Energy SoC
New SmartBond DA1470x Family Features Small Form Factor with Integrated Applications and 2D Graphics Processors, Voice Activity Detector and Power Management Enables...
- 543Wire Stories
PlayCroco Casino Winner Scoops $1.3m Prize!
One lucky player turns $5 into a million! SYDNEY–(BUSINESS WIRE)–What can $5 get you these days? Well, for one lucky legend at...
- 569Wire Stories
PlayCroco Casino Winner Scoops $1.3m Prize!
One lucky player turns $5 into a million! SYDNEY–(BUSINESS WIRE)–What can $5 get you these days? Well, for one lucky legend at...
- 550Wire Stories
People2.0 Acquires Leading UK-Based Provider of Support Services to Independent Contractors
Merger with the Brookson Group—a broadly recognized, technologically advanced independent contractor support platform—boosts People2.0’s market reach and will serve as gateway to...
- 544Wire Stories
People2.0 Acquires Leading UK-Based Provider of Support Services to Independent Contractors
Merger with the Brookson Group—a broadly recognized, technologically advanced independent contractor support platform—boosts People2.0’s market reach and will serve as gateway to...
- 544Wire Stories
SEE Announces Upcoming Event with the Asia Pacific Financial Community
Tokyo, Japan CHARLOTTE, N.C.–(BUSINESS WIRE)–SEE (Sealed Air NYSE: SEE) will participate in the following event. Ted Doheny, President and CEO, and members...
- 549Wire Stories
SEE Announces Upcoming Event with the Asia Pacific Financial Community
Tokyo, Japan CHARLOTTE, N.C.–(BUSINESS WIRE)–SEE (Sealed Air NYSE: SEE) will participate in the following event. Ted Doheny, President and CEO, and members...
- 642Wire Stories
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor...
- 596Wire Stories
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor...
- 528Wire Stories
Carbon Streaming Announces First Stream Investment in Canada With Will Solutions
Up to US$20 Million for Expansion of Existing Sustainable Community Project in Quebec and Implementation of New Sustainable Community Project in Ontario...
